Topics Topics Help/Instructions Help Edit Profile Profile Member List Register Paatha Gnyapakaalu - Archives from Old DB  
Search New Posts 1 | 2 | 8 Hours Search New Posts 1 | 3 | 7 Days Search Search Tree View Tree View Latest tweets Live Tweets   Hide Images

Rate this post by selecting a number. 1 is the worst and 5 is the best.

    (Worst)    1    2    3    4    5     (Best)

Author Message
Top of pagePrevious messageNext messageBottom of page Link to this message

Entrepreneur
Kurra Bewarse
Username: Entrepreneur

Post Number: 3354
Registered: 05-2011
Posted From: 65.35.45.47

Rating: N/A
Votes: 0

Posted on Thursday, March 04, 2021 - 7:06 pm:   

ORGO is a regenerative medicine company. It offers a portfolio of bioactive and acellular biomaterials products in advanced wound care and surgical biologics, including orthopedics and spine. Its products are designed to treat a variety of patients with repair and regenerative needs. ORGO notes that skin substitutes are a fast-growing yet underpenetrated segment of the advanced wound care market. ORGO sees good growth potential going forward. For 2020, ORGO has guided to revenue of $311-314 mln, up 19-20% yr/yr, so it's a pretty substantial company. ORGO has been expanding its sales force in recent years in order to get the word out on how its products address patients' needs to treat wounds across all the stages of healing. On the M&A front, ORGO recently acquired CPN Biosciences, which significantly enhances its ability to drive growth in the office channel by broadening Organogenesis' physician offering. The stock has been making a strong move since reporting robust Q3 results with revenue growth of 57%, driven by 66% growth in its Advanced Wound Care product segment. These results were well above expectations and exceeded the high end of prior guidance.

Topics | Last Hour | Last Day | Last Week | Tree View | Search | Help/Instructions | Program Credits Administration